Tag - IMMP

Developments

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...

March 19, 2026

Developments

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Immutep (ASX: IMM; NASDAQ: IMMP) and Dr. Reddy’s Laboratories (BSE: 500124; NSE: DRREDDY; NYSE: RDY; NSEIFSC: DRREDDY) have announced that they have entered into a strategic collaboration and exclusive licensing...

December 8, 2025

Markets

Ladenburg starts Immutep at buy; PT $8.30

Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...

August 3, 2021

Markets

Maxim transfers coverage of Immutep at buy; PT $8

Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15. Immutep has a pipeline of...

July 16, 2021

Tag - IMMP

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Ladenburg starts Immutep at buy; PT $8.30

Maxim transfers coverage of Immutep at buy; PT $8

Subscribe